SCHEMBL3886038

SCHEMBL3886038

N#Cc1cccc(C(c2ccc[nH]c2=O)C(c2cccnc2)c2cccnc2)c1

nearest known ligand 0.44

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CYP19A1 P11511 2/20 0.44
KCNA5 P22460 5/20 0.41
VNN1 O95497 1/20 0.39
KCNH2 Q12809 2/20 0.39
MGLL Q99685 1/20 0.37
NEK1 Q96PY6 1/20 0.36
GAA P10253 2/20 0.36
KDM4E B2RXH2 1/20 0.36
ALDH1A1 P00352 1/20 0.36
KMT2A Q03164 1/20 0.36
CHRNB2 P17787 2/20 0.35
CHRNA5 P30532 2/20 0.35
CHRNA4 P43681 2/20 0.35
MAPK1 P28482 1/20 0.35
MCL1 Q07820 1/20 0.35
IDO1 P14902 1/20 0.34
GRM5 P41594 1/20 0.34
CYP17A1 P05093 1/20 0.34
CYP11B1 P15538 1/20 0.34
CYP11B2 P19099 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3886105 0.85 CFTR (0.43) CYP19A1KCNA5GAAKDM4EALDH1A1
SCHEMBL3886037 0.79 CYP19A1 (0.43) CYP19A1KCNA5VNN1KCNH2MGLL
SCHEMBL1378201 0.78 CYP19A1 (0.51) CYP19A1KCNA5VNN1KCNH2MGLL
SCHEMBL1381261 0.75 CYP19A1 (0.49) CYP19A1KCNA5VNN1KCNH2MGLL
SCHEMBL1381350 0.75 CYP19A1 (0.49) CYP19A1KCNA5VNN1KCNH2MGLL
SCHEMBL3895680 0.75 KCNA5 (0.43) CYP19A1KCNA5VNN1KCNH2MGLL
SCHEMBL3892977 0.74 KCNA5 (0.47) CYP19A1KCNA5GAA
SCHEMBL1380955 0.72 CYP19A1 (0.46) CYP19A1KCNA5VNN1KCNH2MGLL
SCHEMBL1240925 0.72 CYP19A1 (0.51) CYP19A1KCNA5VNN1KCNH2MGLL
SCHEMBL9197340 0.72 SMN1; SMN2 (0.57) CYP19A1KCNA5VNN1KCNH2MGLL

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1776355-B1 POTASSIUM CHANNEL INHIBITORS MERCK SHARP & DOHME (US) 2013-06-12 EP disclosed
EP-1776355-B1 POTASSIUM CHANNEL INHIBITORS MERCK SHARP & DOHME (US) 2013-06-12 EP disclosed
US-7569589-B2 Potassium channel inhibitors MERCK & CO., INC. (US) 2009-08-04 US disclosed
US-7569589-B2 Potassium channel inhibitors MERCK & CO., INC. (US) 2009-08-04 US disclosed
US-7569589-B2 Potassium channel inhibitors MERCK & CO., INC. (US) 2009-08-04 US disclosed
US-20060030595-A1 (R)-N-{6-[1-(4-fluorophenyl)-2,2-dipyridin-3-ylethyl]pyridin-2-yl}methanesulfonamide; cardiac arrhythmias MERCK SHARP & DOHME LLC 2006-02-09 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20060030595-A1 (R)-N-{6-[1-(4-fluorophenyl)-2,2-dipyridin-3-ylethyl]pyridin-2-yl}methanesulfonamide; cardiac arrhythmias KCNN2, KCNJ2, KCNH2 CYP19A1 4696/4885KCNA5 14/4885VNN1 1566/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.